Comments on the recently published “Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma”-Reference-Cited by-同舟云学术

Comments on the recently published “Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma”

Published:2015-06-10 Issue:8 Volume:123 Page:449-453
ISSN:1934-662X
Container-title:Cancer Cytopathology
language:en
Short-container-title:Cancer Cytopathology

Author:

Hjerpe Anders¹,Dobra Katalin²

Affiliation:

1. Department of Laboratory Medicine; Division of Pathology; Huddinge University Hospital, Karolinska Institute; Huddinge Sweden

2. Laboratory of Clinical Pathology and Cytology; Division of Pathology; Karolinska Institute; Huddinge Sweden

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group;Husain;Arch Pathol Lab Med,2013

2. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group;Husain;Arch Pathol Lab Med,2009

3. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology;Hjerpe;Acta Cytol,2015

4. Malignant pleural mesothelioma: a comprehensive review;Ismail-Khan;Cancer Control,2006

5. Multimodality treatment of diffuse malignant pleural mesothelioma;Zellos;Semin Oncol,2002

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant-Primary (MAL-P) (Mesothelioma);The International System for Serous Fluid Cytopathology;2020

2. Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations;Pathology International;2019-10-03

3. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers;Cancer Cytopathology;2017-01-31

4. Modern management of malignant pleural mesothelioma;Lung Cancer: Targets and Therapy;2016-05